MR imaging of CNS tumors: Are all contrast agents created the same?

Neuroradiology

Volumn 48, Issue SUPPL. 1, 2006, Pages 3-8

  Essig, Marco ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Brain tumor; Comparative studies; Contrast media; Magnetic resonance

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE;

ARTICLE; BRAIN CANCER; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG CHOICE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGICAL ANATOMY; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SENSITIVITY AND SPECIFICITY;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS;

EID: 33646538846     PISSN: 00283940     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00234-006-1463-3     Document Type: Article

References (30)

1. Brant-Zawadski M, Norman D, Newton TH (1984) Magnetic resonance imaging of the brain: The optimal screening technique. Radiology 152:71-77
2. Muroff LR, Runge VM (1995) The use of MR contrast in neoplastic disease of the brain. Top Magn Reson Imaging 7:137-157
3. Edelmann RR, Hesselink JR, Zlatkin MB (1996) Clinical magnetic resonance imaging, 2nd edn. W.B. Saunders
4. Essig M, Knopp MV, Schoenberg SO et al (1999) Contrast-enhanced fast fluid-attenuated inversion-recovery (FLAIR) MR imaging in the assessment of primary glial tumors and brain metastases. Radiology 210:551-557
5. Erickson BJ, Campeau NG, Schreiner SA et al (2002) Triple-dose contrast/ magnetization transfer suppressed imaging of 'non-enhancing' brain gliomas. J Neurooncol 60:25-29
6. Schneider G, Kirchin MA, Pirovano G et al (2001) Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: Effect of dose on lesion detection and delineation. J Magn Reson Imaging 14:525-539
7. de Haën C, Cabrini M, Akhnana L et al (1999) Gadobenate dimeglumine 0.5 M solution for injection (MultiHance): Pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 23 [Suppl 1]:161-168
8. Yuh WTC, Fisher DJ, Engelken JD et al (1991) MR evaluation of CNS tumors: Dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180:485-491
9. Myhr G, Rinck PA, Børseth A (1992) Gadodiamide injection and gadopentetate dimeglumine: A double-blind study in MR imaging of the CNS. Acta Radiol 33:405-409
10. Valk J, Algra PR, Hazenberg CJ et al (1993) A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 35:173-177
11. Oudkerk M, Sijens PE, van Beek EJ, Kuijpers TJ (1995) Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 30:75-78
12. Greco A, Parker JR, Ratcliffe CG et al (2001) Phase III, randomized, doubleblind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 45:457-63
13. Cavagna FM, Maggioni F, Castelli PM et al (1997) Gd chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780-796
14. Knopp MV, Schoenberg SO, Rehm C et al (2002) Assessment of gadobenate dimeglumine (Gd-BOPTA) for MR angiography: Phase I studies. Invest Radiol 37:706-715
15. Rosati G, Pirovano G, Spinazzi A (1994) Interim results of phase II clinical testing of gadobenate dimeglumine. Invest Radiol 29:S183-S185
16. Ruscalleda J, Kirchin MA, La Noce A et al (1999) Multihance in the assessment of intracranial tumors: Results of phase II clinical studies. J Comput Assist Tomogr 23 [Suppl 1]:S19-S27
17. Baler̀iaux D, Colosimo C, Ruscalleda J et al (2002) Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine. Neuroradiology 44:191-203
18. Schneider G, Kirchin MA, Pirovano G et al (2001) Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: Effect of dose on lesion detection and delineation. J Magn Reson Imaging 14:525-539
19. Runge VM, Armstrong MR, Barr RG et al (2001) A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol 36:65-71
20. Runge V, Parker JR, Donovan M (2002) Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 37:269-280
21. Colosimo C, Ruscalleda J, Korves M et al (2001) Detection of intracranial metastases: A multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol 36:72-81
22. Essig M, Hartmann M, Lodemann KP et al (2001) Comparison of contrast behavior of gadobenate-dimeglumine and Gd-DTPA in intra-axial brain tumors. A double-blind randomized intraindividual cross-over study (in German). Radiologe 41:1063-1071
23. Knopp MV, Runge VM, Essig M et al (2004) Primary and secondary brain tumors: A bicentric intra-individual crossover comparison of gadobenate dimeglumine with gadopentetate dimeglumine for lesion enhancement. Radiology 230:55-64
24. Colosimo C, Knopp MV, Barreau X et al (2004) A comparision of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intra-cranial tumours. Neuroradiology 46:655-665
25. Essig M, Tartaro A, Tartaglione T et al (2006) Enhancing lesions of the brain: Intra-individual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol (in press)
26. Colosimo C, Demaerel P, Tortori-Donati P et al (2005) Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumors in pediatric subjects. Pediatr Radiol 35:501-510
27. Schaefer PW, Hunter GJ, He J et al (2002) Predicting cerebral ischemic infarct volume with diffusion and perfusion MR imaging. AJNR Am J Neuroradiol 23:1785-1794
28. Essig M, Wenz F, Scholdei R et al (2002) Dynamic susceptibility contrastenhanced echo-planar imaging of cerebral gliomas. Effect of contrast medium extravasation. Acta Radiol 43:354-359
29. Essig M, Lodemann KP, LeHuu M et al (2002) Comparison of MultiHance and Gadovist for cerebral MR perfusion imaging in healthy volunteers. Radiologe 42:909-915
30. Essig M, Lodemann KP, LeHuu M et al (2006) Intraindividual comparision of Godobenate Dimeglumine and Godobutrol for cerebral magnetic resonance perfusion imaging at 1.5T. Invest Radiol 41:256-263